MYHEP ALL

Myhepall

Descripition : 

Myhep all is an anti-hepatitis C viral medicine, containing active components known as Sofosbuvir and Velpatasvir available in the strength of 400mg & 100mg respectively. 

velpatasvir is a class of anti-hepatitis C viral drug, called NS5A multiplication complex inhibitors.

This may have combined with other anti-viral agent Sofosbuvir which expels its work by stopping the virus which may causes hepatitis C viral infection from spreading inside the body. 

Myhep all tablet is not a curable; it is only used to control the spreading of disease.

 

MYHEP ALL INDICATION AND USAGE

Myhep all tablets are used only in adult’s patients with long lasting hepatitis C virus caused by genotypes I, II, III, IV, V or VI In two conditions Myhep all tablets are used; 

Without cirrhosis or with compensated cirrhosis (child Pugh A or B) With decompensated cirrhosis by combining with ribavirin (child Pugh C)  

MYHEP ALL MECHANISM OF ACTION

• Both the components in Myhep all tablets are involved in inhibiting nonstructural protein which is essential for viral multiplication. Sofosbuvir is a NS5B inhibitor, whereas Velpatasvir is considered as NS5Ainhibitor Myhep all is a directly acting anti-hepatitis C viral agent. 

• Sofosbuvir leads to produce pharmacologically active uridine analog triphosphate by intracellular metabolism. Sofosbuvir is inserted into viral HCV DNA by NS5B polymerase and act as a chain terminator. Velpatasvir inhibits NS5A protein which is responsible for viral assembly.